Top

Breast Cancer Research and Treatment

Published in:

01-02-2018 | Brief Report

Vitamin D supplementation decreases serum 27-hydroxycholesterol in a pilot breast cancer trial

Authors: Catherine C. Going, Ludmila Alexandrova, Kenneth Lau, Christine Y. Yeh, David Feldman, Sharon J. Pitteri

Published in: Breast Cancer Research and Treatment | Issue 3/2018

Abstract

Purpose

27-hydroxycholesterol (27HC), an endogenous selective estrogen receptor modulator (SERM), drives the growth of estrogen receptor-positive (ER+) breast cancer. 1,25-dihydroxyvitamin D (1,25(OH)₂D), the active metabolite of vitamin D, is known to inhibit expression of CYP27B1, which is very similar in structure and function to CYP27A1, the synthesizing enzyme of 27HC. Therefore, we hypothesized that 1,25(OH)₂D may also inhibit expression of CYP27A1, thereby reducing 27HC concentrations in the blood and tissues that express CYP27A1, including breast cancer tissue.

Methods

27HC, 25-hydroxyvitamin D (25OHD), and 1,25(OH)₂D were measured in sera from 29 breast cancer patients before and after supplementation with low-dose (400 IU/day) or high-dose (10,000 IU/day) vitamin D in the interval between biopsy and surgery.

Results

A significant increase (p = 4.3E−5) in 25OHD and a decrease (p = 1.7E−1) in 27HC was observed in high-dose versus low-dose vitamin D subjects. Excluding two statistical outliers, 25OHD and 27HC levels were inversely correlated (p = 7.0E−3).

Conclusions

Vitamin D supplementation can decrease circulating 27HC of breast cancer patients, likely by CYP27A1 inhibition. This suggests a new and additional modality by which vitamin D can inhibit ER+ breast cancer growth, though a larger study is needed for verification.

Available only for authorised users

Umetani M, Domoto H, Gormley AK, Yuhanna IS, Cummins CL, Javitt NB, Korach KS, Shaul PW, Mangelsdorf DJ (2007) 27-Hydroxycholesterol is an endogenous SERM that inhibits the cardiovascular effects of estrogen. Nat Med 13:1185–1192CrossRefPubMed

DuSell CD, Umetani M, Shaul PW, Mangelsdorf DJ, McDonnell DP (2008) 27-Hydroxycholesterol is an endogenous selective estrogen receptor modulator. Mol Endocrinol 22:65–77CrossRefPubMed

Wu Q, Ishikawa T, Sirianni R, Tang H, McDonald JG, Yuhanna IS, Thompson B, Girard L, Mineo C, Brekken RA, Umetani M, Euhus DM, Xie Y, Shaul PW (2013) 27-Hydroxycholesterol promotes cell-autonomous ER-positive breast cancer growth. Cell Rep 5:637–645CrossRefPubMedPubMedCentral

Nelson ER, Wardell SE, McDonnell DP (2015) Abstract A82: the cholesterol metabolite, 27-hydroxycholesterol, promotes breast cancer metastasis. Cancer Immunol Res 3:A82CrossRef

Nelson ER, Wardell SE, Jasper JS, Park S, Suchindran S, Howe MK, Carver NJ, Pillai RV, Sullivan PM, Sondhi V, Umetani M, Geradts J, McDonnell DP (2013) 27-Hydroxycholesterol links hypercholesterolemia and breast cancer pathophysiology. Science 342:1094–1098CrossRefPubMedPubMedCentral

Kimbung S, Chang C, Bendahl P-O, Dubois L, Thompson WJ, McDonnell DP, Borgquist S (2017) Impact of 27-hydroxylase (CYP27A1) and 27-hydroxycholesterol in breast cancer. Endocr Relat Cancer 24:339–349CrossRefPubMed

Haussler MR, Whitfield GK, Kaneko I, Haussler CA, Hsieh D, Hsieh JC, Jurutka PW (2013) Molecular mechanisms of vitamin D action. Calcif Tissue Int 92:77–98CrossRefPubMed

Krishnan AV, Feldman D (2011) Mechanisms of the anti-cancer and anti-inflammatory actions of vitamin D. Annu Rev Pharmacol Toxicol 51:311–336CrossRefPubMed

Feldman D, Krishnan AV, Swami S, Giovannucci E, Feldman BJ (2014) The role of vitamin D in reducing cancer risk and progression. Nat Rev Cancer 14:342–357CrossRefPubMed

10.

Luo W, Johnson CS, Trump DL (2016) Vitamin D signaling modulators in cancer therapy. Vitam Horm 100:433–472CrossRefPubMed

11.

Takeyama K-i, Kitanaka S, Sato T, Kobori M, Yanagisawa J, Kato S (1997) 25-Hydroxyvitamin D₃ 1α-hydroxylase and vitamin D synthesis. Science 277:1827–1830CrossRefPubMed

12.

Murayama A, Takeyama K-i, Kitanaka S, Kodera Y, Hosoya T, Kato S (1998) The promoter of the human 25-hydroxyvitamin D3 1 alpha-hydroxylase gene confers positive and negative responsiveness to PTH, calcitonin, and 1 alpha,25(OH)2D3. Biochem Biophys Res Commun 249:11–16CrossRefPubMed

13.

Jones G, Prosser DE, Kaufmann M (2014) Cytochrome P450-mediated metabolism of vitamin D. J Lipid Res 55:13–31CrossRefPubMedPubMedCentral

14.

Axen E, Postland H, Sioberg H, Wikvall K (1994) Liver mitochondrial cytochrome P450 CYP27 and recombinant-expressed human CYP27 catalyze 1 alpha-hydroxylation of 25-hydroxyvitamin D3. Proc Natl Acad Sci USA 91:10014–10018CrossRefPubMedPubMedCentral

15.

Sawada N, Sakaki T, Ohta M, Inouye K (2000) Metabolism of vitamin D3 by CYP27A1. Biochem Biophys Res Commun 273:977–984CrossRefPubMed

16.

Yin K, You Y, Swier V, Tang L, Radwan MM, Pandya AN, Agrawal DK (2015) Vitamin D protects against atherosclerosis via regulation of cholesterol efflux and macrophage polarization in hypercholesterolemic swine. Arterioscler Thromb Vasc Biol 35:2432–2442CrossRefPubMedPubMedCentral

17.

Barchetta I, Carotti S, Labbadia G, Gentilucci UV, Muda AO, Angelico F, Silecchia G, Leonetti F, Fraioli A, Picardi A, Morini S, Cavallo MG (2012) Liver vitamin D receptor, CYP2R1, and CYP27A1 expression: relationship with liver histology and vitamin D3 levels in patients with nonalcoholic steatohepatitis or hepatitis C virus. Hepatology 56:2180–2187CrossRefPubMed

18.

McDonald JG, Smith DD, Stiles AR, Russell DW (2012) A comprehensive method for extraction and quantitative analysis of sterols and secosteroids from human plasma. J Lipid Res 53:1399–1409CrossRefPubMedPubMedCentral

19.

Vanlint S (2013) Vitamin D and Obesity. Nutrients 5:949–956CrossRefPubMedPubMedCentral

20.

Swami S, Krishnan AV, Williams J, Aggarwal A, Albertelli MA, Horst RL, Feldman BJ, Feldman D (2016) Vitamin D mitigates the adverse effects of obesity on breast cancer in mice. Endocr Relat Cancer 23:251–264CrossRefPubMedPubMedCentral

21.

Swami S, Krishnan AV, Wang JY, Jensen K, Horst R, Albertelli MA, Feldman D (2012) Dietary vitamin D(3) and 1,25-dihydroxyvitamin D(3) (calcitriol) exhibit equivalent anticancer activity in mouse xenograft models of breast and prostate cancer. Endocrinology 153:2576–2587CrossRefPubMedPubMedCentral

22.

Townsend K, Banwell CM, Guy M, Colston KW, Mansi JL, Stewart PM, Campbell MJ, Hewison M (2005) Autocrine metabolism of vitamin D in normal and malignant breast tissue. Clin Cancer Res 11:3579–3586CrossRefPubMed

23.

Kemmis CM, Salvador SM, Smith KM, Welsh J (2006) Human mammary epithelial cells express CYP27B1 and are growth inhibited by 25-hydroxyvitamin D-3, the major circulating form of vitamin D-3. J Nutr 136:887–892CrossRefPubMed

24.

Krishnan AV, Swami S, Feldman D (2013) Equivalent anticancer activities of dietary vitamin D and calcitriol in an animal model of breast cancer: importance of mammary CYP27B1 for treatment and prevention. J Steroid Biochem Mol Biol 136:289–295CrossRefPubMed

25.

Wagner D, Trudel D, Van der Kwast T, Nonn L, Giangreco AA, Li D, Dias A, Cardoza M, Laszlo S, Hersey K, Klotz L, Finelli A, Fleshner N, Vieth R (2013) Randomized clinical trial of vitamin D3 doses on prostatic vitamin D metabolite levels and ki67 labeling in prostate cancer patients. J Clin Endocrinol Metab 98:1498–1507CrossRefPubMed

26.

Aggarwal A, Feldman D, Feldman BJ (2017) Identification of tumor-autonomous and indirect effects of vitamin D action that inhibit breast cancer growth and tumor progression. J Steroid Biochem Mol Biol. https://doi.org/10.1016/j.jsbmb.2017.07.003 PubMed

27.

Williams JD, Aggarwal A, Swami S, Krishnan AV, Ji L, Albertelli MA, Feldman BJ (2016) Tumor autonomous effects of vitamin D deficiency promote breast cancer metastasis. Endocrinology 157:1341–1347CrossRefPubMedPubMedCentral

28.

Nguyen VTM, Barozzi I, Faronato M, Lombardo Y, Steel JH, Patel N, Darbre P, Castellano L, Győrffy B, Woodley L, Meira A, Patten DK, Vircillo V, Periyasamy M, Ali S, Frige G, Minucci S, Coombes RC, Magnani L (2015) Differential epigenetic reprogramming in response to specific endocrine therapies promotes cholesterol biosynthesis and cellular invasion. Nat Commun 6:10044CrossRefPubMedPubMedCentral

Title: Vitamin D supplementation decreases serum 27-hydroxycholesterol in a pilot breast cancer trial
Authors: Catherine C. Going
Ludmila Alexandrova
Kenneth Lau
Christine Y. Yeh
David Feldman
Sharon J. Pitteri
Publication date: 01-02-2018
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 3/2018
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-017-4562-4

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2018

Impact of microinvasion on breast cancer mortality in women with ductal carcinoma in situ

Does the elevation of CAMLs predict metastatic breast cancer patients’ survival?

Young age at first pregnancy does protect against early onset breast cancer in BRCA1 and BRCA2 mutation carriers

Ribociclib with letrozole vs letrozole alone in elderly patients with hormone receptor-positive, HER2-negative breast cancer in the randomized MONALEESA-2 trial

Safety of fertility preservation in breast cancer patients in a register-based matched cohort study

Breast cancer-related paraneoplastic neurologic disease

Keynote webinar | Spotlight on antibody–drug conjugates in cancer